Canine Cutaneous Haemangiosarcoma: Biomarkers and Survival

Area of Science:

• Veterinary Oncology
• Immunohistochemistry
• Canine Neoplasms

Background:

• Cutaneous haemangiosarcoma (cHSA) is a common, aggressive vascular tumor in dogs, often linked to poor prognosis.
• Solar radiation is a suspected factor in light-skinned, short-haired dogs, but prognostic markers for cHSA are lacking.
• Understanding cHSA's biological behavior and identifying prognostic factors are crucial for developing targeted therapies.

Purpose of the Study:

• To evaluate immunohistochemical markers (FVIII, COX-2, VEGF, PCNA, Caspase-3) in canine cHSA.
• To correlate marker expression with overall survival (OS) in dogs with cHSA.
• To identify prognostic factors influencing cHSA outcomes.

Main Methods:

• Sixty canine cHSA samples were analyzed using immunohistochemistry for FVIII, COX-2, VEGF, PCNA, and Caspase-3.
• Results were correlated with overall survival using a competitive risks model.
• Clinical variables (age, sex, breed, tumor invasiveness, differentiation, mitotic rate, size) were also analyzed.

Main Results:

• All markers were expressed (80-100% of samples), with strong PCNA and Caspase-3, and weak-to-moderate FVIII, COX-2, VEGF.
• Median OS was 12 months; clinical variables like age, tumor size, and invasiveness did not significantly correlate with survival.
• No immunohistochemical marker expression or intensity correlated with OS, though COX-2 and VEGF were frequently detected.

Conclusions:

• Standard immunohistochemical markers and clinical factors showed no significant correlation with overall survival in canine cHSA.
• Frequent expression of COX-2 and VEGF suggests their potential as therapeutic targets for canine cHSA.
• Further investigation into COX-2 and VEGF pathways may lead to novel treatment strategies for canine cutaneous haemangiosarcoma.